ATE466570T1 - Wässrige hfsh-formulierung - Google Patents
Wässrige hfsh-formulierungInfo
- Publication number
- ATE466570T1 ATE466570T1 AT06798894T AT06798894T ATE466570T1 AT E466570 T1 ATE466570 T1 AT E466570T1 AT 06798894 T AT06798894 T AT 06798894T AT 06798894 T AT06798894 T AT 06798894T AT E466570 T1 ATE466570 T1 AT E466570T1
- Authority
- AT
- Austria
- Prior art keywords
- hfsh
- formulation
- aqueous
- hfsh formulation
- aqueous hfsh
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050089853A KR101105871B1 (ko) | 2005-09-27 | 2005-09-27 | 인 난포자극호르몬의 안정한 용액 제형 |
| PCT/KR2006/003811 WO2007037607A1 (en) | 2005-09-27 | 2006-09-25 | Hfsh aqueous formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE466570T1 true ATE466570T1 (de) | 2010-05-15 |
Family
ID=37899985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06798894T ATE466570T1 (de) | 2005-09-27 | 2006-09-25 | Wässrige hfsh-formulierung |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20110201554A1 (de) |
| EP (1) | EP1928413B1 (de) |
| JP (1) | JP5364374B2 (de) |
| KR (1) | KR101105871B1 (de) |
| CN (1) | CN101272764B (de) |
| AR (1) | AR056538A1 (de) |
| AT (1) | ATE466570T1 (de) |
| AU (1) | AU2006295570B2 (de) |
| BR (1) | BRPI0616300A2 (de) |
| DE (1) | DE602006014175D1 (de) |
| ES (1) | ES2345058T3 (de) |
| GT (1) | GT200600431A (de) |
| PE (1) | PE20070437A1 (de) |
| RU (1) | RU2407514C2 (de) |
| SA (1) | SA06270332B1 (de) |
| TR (1) | TR200801968T2 (de) |
| TW (1) | TW200735897A (de) |
| WO (1) | WO2007037607A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8617568B2 (en) | 2007-07-10 | 2013-12-31 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
| AU2009203809B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
| EP2412385A1 (de) * | 2008-02-08 | 2012-02-01 | BioGeneriX AG | Flüssige Formulierung von FSH |
| PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| US8329649B2 (en) | 2008-11-04 | 2012-12-11 | Aska Pharmaceutical Co., Ltd. | Aqueous composition containing follicle-stimulating hormone and histidine |
| KR101853606B1 (ko) | 2009-07-06 | 2018-05-03 | 사노피-아벤티스 도이칠란트 게엠베하 | 메티오닌을 함유하는 수성 인슐린 제제 |
| DK2498802T3 (en) | 2009-11-13 | 2015-04-13 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine |
| KR101337322B1 (ko) | 2009-11-13 | 2013-12-06 | 사노피-아벤티스 도이칠란트 게엠베하 | Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물 |
| WO2011099036A2 (en) * | 2010-02-12 | 2011-08-18 | Intas Biopharmaceuticals Limited | Liquid formulation of follicle stimulating hormone |
| EP2417982A1 (de) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilisierung von Gonadotropinen |
| ES2606554T3 (es) | 2010-08-30 | 2017-03-24 | Sanofi-Aventis Deutschland Gmbh | Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| PL2750699T3 (pl) | 2011-08-29 | 2015-12-31 | Sanofi Aventis Deutschland | Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| AP2016009159A0 (en) * | 2013-11-12 | 2016-04-30 | Cadila Healthcare Ltd | Formulation for gonadotropins |
| SG11201604706TA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
| CN112957455A (zh) | 2014-01-09 | 2021-06-15 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂 |
| EP3091965A1 (de) | 2014-01-09 | 2016-11-16 | Sanofi | Stabilisierte glycerinfreie pharmazeutische formulierungen von insulinanaloga und/oder insulinderivaten |
| AU2015359376B2 (en) | 2014-12-12 | 2021-09-09 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| US11738068B2 (en) | 2018-06-25 | 2023-08-29 | Jcr Pharmaceuticals Co., Ltd. | Protein-containing aqueous liquid formulation |
| CN115429751B (zh) * | 2022-09-21 | 2023-11-17 | 景泽生物医药(合肥)股份有限公司 | 一种人重组卵泡刺激素注射剂及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270057A (en) * | 1990-03-20 | 1993-12-14 | Akzo N.V. | Stabilized gonadotropin containing preparations |
| IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
| RU2062619C1 (ru) * | 1994-02-08 | 1996-06-27 | Курский сельскохозяйственный институт им.проф.И.И.Иванова | Способ получения препарата фолликулостимулирующего гормона из аденогипофизов животных |
| ES2166841T3 (es) * | 1995-03-21 | 2002-05-01 | Applied Research Systems | Formulaciones liquidas de hcg. |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| IL140984A0 (en) * | 1998-07-23 | 2002-02-10 | Lilly Co Eli | Fsh and fsh variant formulations, products and methods |
| CA2369451C (en) * | 1999-04-08 | 2009-09-22 | Genentech, Inc. | Composition based on oppositely-charged polypeptides |
| US7514239B2 (en) * | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
| US20020058029A1 (en) * | 2000-09-18 | 2002-05-16 | Nabil Hanna | Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination |
| ES2392073T3 (es) * | 2001-11-08 | 2012-12-04 | Abbott Biotherapeutics Corp. | Formulación farmacéutica líquida estable de anticuerpos IGG |
| NZ535008A (en) * | 2002-02-08 | 2005-09-30 | Alkermes Inc | Polymer-based compositions for sustained release |
| US20050232899A1 (en) * | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| CN1195069C (zh) * | 2002-11-28 | 2005-03-30 | 南京医科大学 | 人卵泡刺激素β亚基单克隆抗体的制备方法 |
| AU2004226666B9 (en) * | 2003-04-02 | 2010-04-08 | Ares Trading S.A. | Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant |
| US20060069021A1 (en) * | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
| MY139088A (en) * | 2005-02-21 | 2009-08-28 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
| WO2006138181A2 (en) * | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| EP2412385A1 (de) * | 2008-02-08 | 2012-02-01 | BioGeneriX AG | Flüssige Formulierung von FSH |
-
2005
- 2005-09-27 KR KR1020050089853A patent/KR101105871B1/ko not_active Expired - Lifetime
-
2006
- 2006-09-01 TW TW095132376A patent/TW200735897A/zh unknown
- 2006-09-19 SA SA06270332A patent/SA06270332B1/ar unknown
- 2006-09-21 PE PE2006001144A patent/PE20070437A1/es not_active Application Discontinuation
- 2006-09-25 RU RU2008111632/15A patent/RU2407514C2/ru active
- 2006-09-25 AU AU2006295570A patent/AU2006295570B2/en active Active
- 2006-09-25 US US12/066,190 patent/US20110201554A1/en not_active Abandoned
- 2006-09-25 DE DE602006014175T patent/DE602006014175D1/de active Active
- 2006-09-25 TR TR2008/01968T patent/TR200801968T2/xx unknown
- 2006-09-25 EP EP06798894A patent/EP1928413B1/de not_active Revoked
- 2006-09-25 JP JP2008532167A patent/JP5364374B2/ja active Active
- 2006-09-25 GT GT200600431A patent/GT200600431A/es unknown
- 2006-09-25 AT AT06798894T patent/ATE466570T1/de not_active IP Right Cessation
- 2006-09-25 WO PCT/KR2006/003811 patent/WO2007037607A1/en not_active Ceased
- 2006-09-25 ES ES06798894T patent/ES2345058T3/es active Active
- 2006-09-25 BR BRPI0616300-9A patent/BRPI0616300A2/pt not_active Application Discontinuation
- 2006-09-25 CN CN2006800355835A patent/CN101272764B/zh active Active
- 2006-09-26 AR ARP060104208A patent/AR056538A1/es not_active Application Discontinuation
-
2016
- 2016-05-04 US US15/146,250 patent/US20160243242A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070035232A (ko) | 2007-03-30 |
| PE20070437A1 (es) | 2007-04-26 |
| JP2009509953A (ja) | 2009-03-12 |
| TW200735897A (en) | 2007-10-01 |
| ES2345058T3 (es) | 2010-09-14 |
| SA06270332B1 (ar) | 2011-01-15 |
| WO2007037607A1 (en) | 2007-04-05 |
| US20160243242A1 (en) | 2016-08-25 |
| CN101272764B (zh) | 2011-05-04 |
| AU2006295570B2 (en) | 2012-08-30 |
| US20110201554A1 (en) | 2011-08-18 |
| AR056538A1 (es) | 2007-10-10 |
| BRPI0616300A2 (pt) | 2011-06-14 |
| JP5364374B2 (ja) | 2013-12-11 |
| GT200600431A (es) | 2007-08-28 |
| CN101272764A (zh) | 2008-09-24 |
| RU2008111632A (ru) | 2009-10-10 |
| DE602006014175D1 (de) | 2010-06-17 |
| EP1928413A1 (de) | 2008-06-11 |
| TR200801968T2 (tr) | 2008-06-23 |
| EP1928413A4 (de) | 2008-12-03 |
| KR101105871B1 (ko) | 2012-01-16 |
| AU2006295570A1 (en) | 2007-04-05 |
| RU2407514C2 (ru) | 2010-12-27 |
| EP1928413B1 (de) | 2010-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006014175D1 (de) | Wässrige hfsh-formulierung | |
| ITMI20050728A1 (it) | Formulazione innovativa | |
| DE602006009656D1 (de) | 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü-pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung | |
| DK1928882T3 (da) | (s)-n-methylnaltrexon | |
| DK1968631T3 (da) | Vaccine | |
| DE602006014304D1 (de) | Sprühvorrichtung | |
| DE602006015684D1 (de) | Sprühvorrichtung | |
| DE602006012066D1 (de) | Daraus | |
| DE602006014297D1 (de) | Sprühvorrichtung | |
| DK1855633T3 (da) | Tampon | |
| ATE537171T1 (de) | Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e | |
| DE602006010581D1 (de) | 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate | |
| ATE487718T1 (de) | Substituierte bizyklische pyrimidonderivate | |
| DK1868586T3 (da) | Antiinflammatorisk formulering | |
| DK1885805T3 (da) | Vandig overtrækssammensætning | |
| FR2895386B1 (fr) | Plieuse | |
| ATE485294T1 (de) | Azaindol-2-carboxamid-derivate | |
| ATE527255T1 (de) | Aryl-isoxazol-4-yl-imidazol-derivate | |
| DK1971588T3 (da) | Tiglien-3-onderivater | |
| DE602006018502D1 (de) | Ng | |
| DE602006002071D1 (de) | Schiffandockseinrichtung | |
| EP1852499A4 (de) | Neurotisationsförderndes agens | |
| DE602006017660D1 (de) | Maskenrohlinge | |
| DE602005023501D1 (de) | Radhausbau | |
| NL1031705A1 (nl) | Aminozuurderivaten. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |